Institutional members access full text with Ovid®

Share this article on:

Cutaneous Lymphomas: An Update. Part 1 T-Cell and Natural Killer/T-Cell Lymphomas and Related Conditions

Kempf, Werner MD*,†; Kazakov, Dmitry V. MD, PhD; Kerl, Katrin MD§

The American Journal of Dermatopathology: February 2014 - Volume 36 - Issue 2 - p 105–123
doi: 10.1097/DAD.0b013e318289b1db
CME Article

Abstract: Primary cutaneous T-cell lymphomas (CTCL) represent the majority of cutaneous lymphomas (CLs) and are a spectrum of diseases with a wide variety of clinical, histological, and phenotypic features and diverse biologic behavior. This review focuses on the observations on new variants of CTCL and recent developments in deciphering the pathogenetic mechanisms, which have implication for the nosologic concepts and future classification of CLs. Variants of mycosis fungoides (MF) such as the unilesional and the papular form have been characterized in more detail. Studies analyzed the expression of CD30 and PD-1 in MF and other forms of CTCL. New variants in the group of cutaneous CD30+ lymphoproliferative disorders include the epidermotropic CD8+ variant of lymphomatoid papulosis (type D) and angiocentric lymphomatoid papulosis (type E), which histologically mimic aggressive lymphomas, and therefore may be diagnostically challenging. Cutaneous proliferations of T cell–expressing markers of follicular helper T cells (PD-1, CXCL-13, and bcl-6) display a prognostically heterogeneous group. There is an increasing spectrum of CTCL with the expression of CD8 by tumor cells, including CD8+ MF, CD8+ forms of cutaneous CD30+ lymphoproliferative disorders, and CD8+ small/medium-sized lymphoproliferations, which are not included as distinct entities in the World Health Organization–European Organization for Research and Treatment of Cancer for CLs and the World Health Organization classification. Unusual presentations and incomplete phenotypes of blastic neoplasm of plasmacytoid dendritic cells are discussed. Clinicopathologic correlation is mandatory for the diagnosis of primary CLs. Analysis of genetic and epigenetic alterations in CLs revealed new diagnostic markers and putative targets for therapy of aggressive forms of CLs.

*Dermatopathologist and Dermatologist, Kempf und Pfaltz, Histologische Diagnostik, Zürich, Switzerland;

Professor, Department of Dermatology, University Hospital Zürich, Switzerland;

Dermatopathologist and Dermatologist, Professor, Department of Pathology, Medical Faculty in Pilsen, Charles University, Prague, Czech Republic; and

§Dermatopathologist and Dermatologist, Faculty Member, Department of Dermatology, University Hospital Zürich, Switzerland.

Reprints: Werner Kempf, MD, Kempf and Pfaltz, Histologische Diagnostik, Seminarstrasse 1, CH-8042 Zürich, Switzerland (e-mail: kempf@kempf-pfaltz.ch).

All authors and staff in a position to control the content of this CME activity and their spouses/life partners (if any) have disclosed that they have no financial relationships with, or financial interests in, any commercial organizations pertaining to this educational activity.

© 2014 by Lippincott Williams & Wilkins.